19-8589243-G-C

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_030957.4(ADAMTS10):​c.2157C>G​(p.Ala719Ala) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00557 in 1,612,584 control chromosomes in the GnomAD database, including 43 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. A719A) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0042 ( 2 hom., cov: 31)
Exomes 𝑓: 0.0057 ( 41 hom. )

Consequence

ADAMTS10
NM_030957.4 splice_region, synonymous

Scores

2
Splicing: ADA: 0.00009434
2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: -1.26

Publications

3 publications found
Variant links:
Genes affected
ADAMTS10 (HGNC:13201): (ADAM metallopeptidase with thrombospondin type 1 motif 10) This gene belongs to the ADAMTS (a disintegrin and metalloproteinase domain with thrombospondin type-1 motifs) family of zinc-dependent proteases. ADAMTS proteases are complex secreted enzymes containing a prometalloprotease domain of the reprolysin type attached to an ancillary domain with a highly conserved structure that includes at least one thrombospondin type 1 repeat. They have been demonstrated to have important roles in connective tissue organization, coagulation, inflammation, arthritis, angiogenesis and cell migration. The product of this gene plays a major role in growth and in skin, lens, and heart development. It is also a candidate gene for autosomal recessive Weill-Marchesani syndrome. [provided by RefSeq, Jul 2008]
ADAMTS10 Gene-Disease associations (from GenCC):
  • Weill-Marchesani syndrome 1
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
  • Weill-Marchesani syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.89).
BP6
Variant 19-8589243-G-C is Benign according to our data. Variant chr19-8589243-G-C is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 235214.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-1.26 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00415 (632/152228) while in subpopulation NFE AF = 0.00688 (468/67998). AF 95% confidence interval is 0.00637. There are 2 homozygotes in GnomAd4. There are 268 alleles in the male GnomAd4 subpopulation. Median coverage is 31. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 2 AR,AD gene

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_030957.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
ADAMTS10
NM_030957.4
MANE Select
c.2157C>Gp.Ala719Ala
splice_region synonymous
Exon 18 of 26NP_112219.3
ADAMTS10
NM_001282352.2
c.618C>Gp.Ala206Ala
splice_region synonymous
Exon 5 of 13NP_001269281.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
ADAMTS10
ENST00000597188.6
TSL:5 MANE Select
c.2157C>Gp.Ala719Ala
splice_region synonymous
Exon 18 of 26ENSP00000471851.1
ADAMTS10
ENST00000270328.8
TSL:5
c.2157C>Gp.Ala719Ala
splice_region synonymous
Exon 17 of 25ENSP00000270328.4
ADAMTS10
ENST00000595838.5
TSL:2
c.618C>Gp.Ala206Ala
splice_region synonymous
Exon 5 of 13ENSP00000470501.1

Frequencies

GnomAD3 genomes
AF:
0.00415
AC:
632
AN:
152110
Hom.:
2
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00113
Gnomad AMI
AF:
0.00549
Gnomad AMR
AF:
0.00341
Gnomad ASJ
AF:
0.00317
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00145
Gnomad FIN
AF:
0.00283
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00688
Gnomad OTH
AF:
0.00526
GnomAD2 exomes
AF:
0.00434
AC:
1075
AN:
247862
AF XY:
0.00425
show subpopulations
Gnomad AFR exome
AF:
0.000872
Gnomad AMR exome
AF:
0.00371
Gnomad ASJ exome
AF:
0.00469
Gnomad EAS exome
AF:
0.0000546
Gnomad FIN exome
AF:
0.00233
Gnomad NFE exome
AF:
0.00678
Gnomad OTH exome
AF:
0.00346
GnomAD4 exome
AF:
0.00572
AC:
8348
AN:
1460356
Hom.:
41
Cov.:
33
AF XY:
0.00575
AC XY:
4177
AN XY:
726570
show subpopulations
African (AFR)
AF:
0.000777
AC:
26
AN:
33476
American (AMR)
AF:
0.00382
AC:
171
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00432
AC:
113
AN:
26132
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.00181
AC:
156
AN:
86252
European-Finnish (FIN)
AF:
0.00246
AC:
128
AN:
52012
Middle Eastern (MID)
AF:
0.00122
AC:
7
AN:
5728
European-Non Finnish (NFE)
AF:
0.00675
AC:
7502
AN:
1111956
Other (OTH)
AF:
0.00406
AC:
245
AN:
60376
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.481
Heterozygous variant carriers
0
569
1138
1708
2277
2846
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
270
540
810
1080
1350
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00415
AC:
632
AN:
152228
Hom.:
2
Cov.:
31
AF XY:
0.00360
AC XY:
268
AN XY:
74444
show subpopulations
African (AFR)
AF:
0.00113
AC:
47
AN:
41546
American (AMR)
AF:
0.00340
AC:
52
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.00317
AC:
11
AN:
3470
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5172
South Asian (SAS)
AF:
0.00145
AC:
7
AN:
4822
European-Finnish (FIN)
AF:
0.00283
AC:
30
AN:
10618
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00688
AC:
468
AN:
67998
Other (OTH)
AF:
0.00521
AC:
11
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
34
68
102
136
170
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00381
Hom.:
0
Bravo
AF:
0.00411
Asia WGS
AF:
0.00115
AC:
4
AN:
3478
EpiCase
AF:
0.00551
EpiControl
AF:
0.00682

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:6
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Feb 02, 2016
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Aug 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ADAMTS10: BP4, BP7, BS2

Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Weill-Marchesani syndrome Benign:1
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease.

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.89
CADD
Benign
0.0050
DANN
Benign
0.35
PhyloP100
-1.3
Mutation Taster
=76/24
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.000094
dbscSNV1_RF
Benign
0.020
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs150468696; hg19: chr19-8654127; API